| Dr Jeffrey Lee Metzner, MD | |
|
3300 E 1st Ave, Suite 590, Denver, CO 80206-5810 | |
| (303) 355-6842 | |
| (303) 322-2155 |
| Full Name | Dr Jeffrey Lee Metzner |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 3300 E 1st Ave, Denver, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003887126 | NPI | - | NPPES |
| 01200070 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 20007 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Lee Metzner, MD 3300 E 1st Ave, Suite 590, Denver, CO 80206-5810 Ph: (303) 355-6842 | Dr Jeffrey Lee Metzner, MD 3300 E 1st Ave, Suite 590, Denver, CO 80206-5810 Ph: (303) 355-6842 |
News Archive
In many cases, a complex interplay between our genes and the environment governs whether or not we will develop a certain disease. Interestingly though, researchers are discovering that the genetic component of disease predisposition may depend on our ethnic background.
Luna Innovations Incorporated has announced the award of a $1.6 million Research Project Grant (R01) from the National Institutes of Health (NIH) to investigate the use of fullerene-based nanomedicines as a pathway to treat allergies and other inflammatory diseases.
Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.
Two proteins are in a tug of war that determines how much the body makes of superoxide, a highly reactive and potentially destructive product of oxygen that's dramatically elevated in cardiovascular disease, researchers report.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).
› Verified 8 days ago
Stefan Michael Bumol, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4455 E 12th Ave, Denver, CO 80220 Phone: 303-504-7700 | |
Dr. Todd M. Kline, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 155 S Madison St, 216, Denver, CO 80209 Phone: 720-360-6375 | |
Gary Lee Martz, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1721 E 19th Ave, Suite 528, Denver, CO 80218 Phone: 303-813-1400 Fax: 303-813-1401 | |
James Trevor Mcnutt, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4545 E 9th Ave, Suite 510, Denver, CO 80220 Phone: 303-321-0700 Fax: 303-321-0811 | |
Dr. Lori Greene, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 10350 E Dakota Ave, Denver, CO 80247 Phone: 303-338-3800 | |
Dr. Katherine Riva, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-724-6019 |